New River Pharmaceuticals Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: Radford VA United States (1996)
Status: Acquired by Shire (2007) → now Takeda (2018)

Organization Overview

First Clinical Trial
2004
NCT00557011
First Marketed Drug
1996
perphenazine (trilafon)
First NDA Approval
2007
lisdexamfetamine (vyvanse)
Last Known Activity
2007

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

NEW RIVER

Active Ingredients

Marketed Drugs (5)

amitriptyline (elavil) (1965)

doxepin (sinequan) (1972)

iron dextran (1981)

lisdexamfetamine (vyvanse) (2007 NDA)

perphenazine (trilafon) (1965)

Drugs in Phase 3 Trials (1)

lisdexamfetamine (vyvanse) (6 trials)

Drugs in Phase 2 Trials (2)

Key: New River Pharmaceuticals (1) Acquired (1)

adderall (1 trial)

pp4001 (1 trial)

Indications

Approved Indications


 

Attention Deficit Disorder with Hyperactivity

Binge-Eating Disorder

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amphetamine-Related Disorders (Phase 2)

Attention Deficit Disorder with Hyperactivity (Phase 3)

Disease (Phase 3)

Hyperkinesis (Phase 3)

Substance-Related Disorders (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 3